Pharmacogenetics in geriatric medicine: Challenges and opportunities for clinical practice

Current Drug Metabolism

Volumn 12, Issue 7, 2011, Pages 621-634

  Pilotto, Alberto ^a   Panza, Francesco ^a   Seripa, Davide ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Adverse drug reaction; Drug efficacy; Elderly; Genetics; Pharmacogenetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACETYLSALICYLIC ACID; AZITHROMYCIN; CARRIER PROTEIN; CHOLINESTERASE INHIBITOR; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450 2A1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DONEPEZIL; DRUG METABOLIZING ENZYME; DRUG RECEPTOR; ERYTHROMYCIN; FLUOROURACIL; GENE PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MERCAPTOPURINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TELITHROMYCIN; TICLOPIDINE; UNINDEXED DRUG; WARFARIN;

AGING; ALZHEIMER DISEASE; BLEEDING; CLINICAL PRACTICE; DEPRESSION; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG TREATMENT FAILURE; GASTROINTESTINAL HEMORRHAGE; HUMAN; PHARMACOGENETICS; PREVALENCE; REVIEW;

AGED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG TOXICITY; GENETIC LOCI; GERIATRICS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 79961077008     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011796504545     Document Type: Review

References (146)

1. Wilkinson, G.R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med., 2005, 21(352), 2211-2221.
2. Ingelman-Sundberg, M.; Rodriguez-Antona, C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos. Trans. R. Soc. Lond. B Biol. Sci., 2005, 360(1460), 1563-1570.
3. Franceschi, M.; Scarcelli, C.; Niro, V.; Seripa, D.; Pazienza, A.M.; Pepe, G.; Colusso, A.M.; Pacilli, L.; Pilotto, A. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf., 2008, 31(6), 545-556. (Pubitemid 351693687)
4. Roden, D.M.; Altman, R.B.; Benowitz, N.L.; Flockhart, D.A.; Giacomini, K.M.; Johnson, J.A.; Krauss, R.M.; McLeod, H.L.; Ratain, M.J.; Relling, M.V.; Ring, H.Z.; Shuldiner, A.R.; Weinshilboum, R.M.; Weiss, S.T.; Pharmacogenetics Research Network. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med., 2006, 145(10), 749-757. (Pubitemid 351650355)
5. Nebert, D.W.; Zhang, G.; Vesell, E.S. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab. Rev., 2008, 40(2), 187-224. (Pubitemid 352000946)
6. Conney, A.H.; Miller, E.C.; Miller, J.A. Substrate-induced synthesis and other properties of benzpyrene hydroxylase in rat liver. J. Biol. Chem., 1957, 228(2), 753-766.
7. Brodie, B.B.; Gillette, J.R.; La Du, B.N. Enzymatic metabolism of drugs and other foreign compounds. Annu. Rev. Biochem., 1958, 27(4), 427-454.
8. Omura, T.; Sato, R. A new cytochrome in liver microsomes. J. Biol. Chem., 1962, 237, 1375-1376.
9. Cooper, D.Y.; Estabrook, R.W.; Rosenthal, O. The stoichiometry of C21 hydroxylation of steroids by adrenocortical microsomes. J. Biol. Chem., 1963, 238, 1320-1323.
10. Cooper, D.Y.; Levin, S.; Narasimhulu, S.; Rosenthal, O. Photochemical action spectrum of the terminal oxidase of mixed function oxidase systems. Science, 1965, 147, 400-402.
11. Wiebel, F.J.; Selkirk, J.K.; Gelboin, H.V.; Haugen, D.A.; van der Hoeven, T.A.; Coon, M.J. Position-specific oxygenation of benzo(a)pyrene by different forms of purified cytochrome P-450 from rabbit liver. Proc. Natl. Acad. Sci. U.S.A., 1975, 72(10), 3917-3920.
12. Cheng, K.C.; Schenkman, J.B. Purification and characterization of two constitutive forms of rat liver microsomal cytochrome P-450. J. Biol. Chem., 1982, 257(5), 2378-2385.
13. Mahgoub, A.; Idle, J.R.; Dring, L.G.; Lancaster, R.; Smith, R.L. Polymorphic hydroxylation of debrisoquine in man. Lancet, 1977, 2(8038), 584-586. (Pubitemid 8176607)
14. Eichelbaum, M.; Spannbrucker, N.; Steincke, B.; Dengler, H.J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol., 1979, 16(3), 183-187. (Pubitemid 10194487)
15. Bertilsson, L.; Dengler, H.J.; Eichelbaum, M.; Schulz, H.U. (1980) Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur. J. Clin. Pharmacol., 1980, 17(2), 153-155. (Pubitemid 10149749)
16. Evans, D.A.; Mahgoun, A.; Sloan, T.P.; Idle, J.R.; Smith, R.L. (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet., 1980, 17(2), 102-105. (Pubitemid 10107632)
17. Bertilsson, L.; Eichelbaum, M.; Mellström, B.; Säwe, J.; Schulz, H.U.; Sjöqvist, F. Nortryptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci., 1980, 27(18), 1673-1677. (Pubitemid 11220225)
18. Gardiner, S.J.; Begg, E.J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev., 2006, 58(3), 521-590. (Pubitemid 44403684)
19. Nelson, D. An Introductory Lecture on Human P450s. 2007. http://drnelson.utmem.edu/P450.talks.html (Accessed December 23, 2010).
20. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se/ (Accessed December 23, 2010)
21. Oscarson, M.; Ingelman-Sundberg, M. CYP alleles: a web page for nomenclature of human cytochrome P450 alleles. Drug. Metab. Pharmacokin., 2002, 17(6), 491-495.
22. Nelson, D.R.; Koymans, L.; Kamataki, T.; Stegeman, J.J.; Feyereisen, R.; Waxman, D.J.; Waterman, M.R.; Gotoh, O.; Coon, M.J.; Estabrook, R.W.; Gunsalus, I.C.; Nebert, D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 1996, 6(1), 1-42. (Pubitemid 26096749)
23. Trusheim, M.R.; Berndt, E.R.; Douglas, F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov., 2007, 6(4), 287-293. (Pubitemid 46505879)
24. Daly, A.K.; Cholerton, S.; Gregory, W.; Idle, J.R. Metabolic polymorphisms. Pharmacol. Ther., 1993, 57(2), 129-160. (Pubitemid 23175378)
25. Ingelman-Sundberg, M.; Oscarson, M.; McLellan, R.A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci., 1999, 20(8), 342-349. (Pubitemid 29366813)
26. Evans, W.E.; Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999, 286(5439), 487-491.
27. Tomalik-Scharte, D.; Lazar, A.; Fuhr, U.; Kirchheiner, J. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J., 2008, 8(1), 4-15.
28. Caraco, Y. Genes and the response to drugs. N. Engl. J. Med., 2004, 351(27), 2867-2869. (Pubitemid 40051914)
29. Nebert, D.W.; Vesell, E.S. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur. J. Pharmacol., 2004, 500(1-3), 267-280. (Pubitemid 39304014)
30. Nebert, D.W. Inter-individual susceptibility to environmental toxicants- A current assessment. Toxicol. Appl. Pharmacol., 2005, 207(2 Suppl), 34-42.
31. Motsinger, A.A.; Ritchie, M.D.; Reif, D.M. Novel methods for detecting epistasis in pharmacogenomics studies. Pharmacogenomics, 2007, 8(9), 1229-1241. (Pubitemid 47591323)
32. Pilotto, A.; Seripa, D.; Franceschi, M.; Scarcelli, C.; Colaizzo, D.; Grandone, E.; Niro, V.; Andriulli, A.; Leandro, G.; Di Mario, F.; Dallapiccola, B. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology, 2007, 133(2), 465-471. (Pubitemid 47193129)
33. Pilotto, A.; Franceschi, M.; D'Onofrio, G.; Bizzarro, A.; Mangialasche, F.; Cascavilla, L.; Paris, F.; Matera, M.G.; Pilotto, A.; Daniele, A.; Mecocci, P.; Masullo, C.; Dallapiccola, B.; Seripa, D. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in Alzheimer's disease patients. Neurology, 2009, 73(10), 761-767.
34. Seripa, D.; Pilotto, A.; Panza, F.; Matera, M.G.; Pilotto, A. Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res. Rev., 2010, 9(4), 457-474.
35. Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev., 2003, 55(3), 425-461. (Pubitemid 37013212)
36. International Transporter Consortium; Giacomini, K.M.; Huang, S.M.; Tweedie, D.J.; Benet, L.Z.; Brouwer, K.L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K.M.; Hoffmaster, K.A.; Ishikawa, T.; Keppler, D.; Kim, R.B.; Lee, C.A.; Niemi, M.; Polli, J.W.; Sugiyama, Y.; Swaan, P.W.; Ware, J.A.; Wright, S.H.; Yee, S.W.; Zamek-Gliszczynski, M.J.; Zhang, L. Membrane transporters in drug development. Nat. Rev. Drug Discov., 2010, 9(3), 215-236.
37. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H.P.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A., 2000, 97(7), 3473-3478. (Pubitemid 30183327)
38. Kalliokoski, A.; Niemi, M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol., 2009, 158(3), 693-705.
39. Jann, M.W.; Shirley, K.L.; Small, G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet., 2002, 41(10), 719-739. (Pubitemid 34948194)
40. Cummings, J.L. Alzheimer's disease. N. Engl. J. Med., 2004, 351(1), 56-67.
41. Courtney, C.; Farrell, D.; Gray, R.; Hills, R.; Lynch, L.; Sellwood, E.; Edwards, S.; Hardyman, W.; Raftery, J.; Crome, P.; Lendon, C.; Shaw, H.; Bentham, P.; AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet, 2004, 363(9427), 2105-2115.
42. Tiseo, P.J.; Perdomo, C.A.; Friedhoff, L.T. Metabolism and elimination of 14C-donepezil in healthy volunteers: a singledose study. Br. J. Clin. Pharmacol., 1988, 46(1), 19-24.
43. Small, G.W.; Rabins, P.V.; Barry, P.P.; Buckholtz, N.S.; DeKosky, S.T.; Ferris, S.H.; Finkel, S.I.; Gwyther, L.P.; Khachaturian, Z.S.; Lebowitz, B.D.; McRae, T.D.; Morris, J.C.; Oakley, F.; Schneider, L.S.; Streim, J.E.; Sunderland, T.; Teri, L.A.; Tune, L.E. Diagnosis and treatment of Alzheimer's disease and related disorders: consensus statement of the American Association of Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA, 1997, 278(16), 1363-1371. (Pubitemid 27449698)
44. Doody, R.S.; Stevens, J.C.; Beck, C.; Dubinsky, R.M.; Kaye, J.A.; Gwyther, L.; Mohs, R.C.; Thal, L.J.; Whitehouse, P.J.; DeKosky, S.T.; Cummings, J.L. Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2001, 56(9), 1154-1166. (Pubitemid 32405709)
45. Varsaldi, F.; Miglio, G.; Scordo, M.G.; Dahl, M.L.; Villa, L.M.; Biolcati, A.; Lombardi, G. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur. J. Clin. Pharmacol., 2006, 62(9), 721-726. (Pubitemid 44289502)
46. Zanger, U.M.; Fischer, J.; Raimundo, S.; Stüven, T.; Evert, B.O.; Schwab, M.; Eichelbaum, M. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics, 2001, 11(7) 573-585. (Pubitemid 32953583)
47. Gaedigk, A.; Ryder, D.L.; Bradford, L.D.; Leeder, J.S. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin. Chem., 2003, 49(6 Pt 1), 1008-1011. (Pubitemid 36623498)
48. Seripa, D.; Bizzarro, A.; Pilotto, A.; D'Onofrio, G.; Vecchione, G.; Gallo, A.P.; Cascavilla, L.; Paris, F.; Grandone, E.; Mecocci, P.; Santini, S.A.; Masullo, C.; Pilotto, A. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenet. Genomics, 2011, 21(4), 225-230.
49. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug. Metab. Rev., 2002, 34(1-2), 83-448. (Pubitemid 34311090)
50. Cacabelos, R. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiatr. Dis. Treat., 2007, 3(3), 303-333. (Pubitemid 47215008)
51. Unützer, J. Clinical practice. Late-life depression. New Engl. J. Med., 2007, 357(22), 2269-2275.
52. Gottfries, C.G. Late life depression. Eur. Arch. Psychiatry Clin. Neurosci., 2001, 251(Suppl2), 57-61.
53. NIH Consensus Conference. Diagnosis and treatment of depression in late life. JAMA, 1992, 268(8), 1018-1024.
54. Stahl, S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 1998, 51(3), 215-235. (Pubitemid 29202172)
55. Caspi, A.; Sugden, K.; Moffitt, T.E.; Taylor, A.; Craig, I.W.; Harrington, H.; McClay, J.; Mill, J.; Martin, J.; Braithwaite, A.; Poulton, R.. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 2003, 301(5631), 386-389. (Pubitemid 36877077)
56. Cervilla, J.A.; Rivera, M.; Molina, E.; Torres-González, F.; Bellón, J.A.; Moreno, B.; de Dios Luna, J.; Lorente, J.A.; de Diego-Otero, Y.; King, M.; Nazareth, I.; Gutiérrez, B.; PREDICT Study Core Group. PREDICT Study CoreGroup, The 5-HTTLPR s/s genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT- Gene Study. Am. J. Med. Genet. B: Neuropsychiatr. Genet., 2006, 141B(8), 912-917. (Pubitemid 44905447)
57. Lesch, K.P.; Bengel, D.; Heils, A.; Sabol, S.Z.; Greenberg, B.D.; Petri, S.; Benjamin, J.; Müller, C.R.; Hamer, D.H.; Murphy, D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science, 1996, 274(5292), 1527-1531. (Pubitemid 26403928)
58. Heils, A.; Teufel, A.; Petri, S.; Stober, G.; Riederer, P.; Bengel, D.; Lesch, K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem., 1996, 66(6), 2621-2624. (Pubitemid 26159101)
59. Gelernter, J.; Freimer, M. PstI RFLP at the SERT locus. Hum. Mol. Genet., 1994, 3(2), 383. (Pubitemid 24060971)
60. Gerretsen, P.; Pollock, B.G. Pharmacogenetics and the serotonin transporter in late-life depression. Expert Opin. Drug Metab. Toxicol., 2008, 4(12),1465-1478.
61. Keers, R.; Uher, R.; Huezo-Diaz, P.; Smith, R.; Jaffee, S.; Rietschel, M.; Henigsberg, N.; Kozel, D.; Mors, O.; Maier, W.; Zobel, A.; Hauser, J.; Souery, D.; Placentino, A.; Larsen, E.R.; Dmitrzak- Weglarz, M.; Gupta, B.; Hoda, F.; Craig, I.; McGuffin, P.; Farmer, A.E.; Aitchison, K.J. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J., 2010, doi:10.1038/tpj.2010.14.
62. Lacasse, J.R.; Leo. J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med., 2005, 2(12), e392.
63. Pilotto, A.; Franceschi, M.; Vitale, D.F.; Zaninelli, A.; Masotti, G.; Rengo, F.; on behalf of F.I.R.I. (Fondazione Italiana Ricerca Invecchiamento) and SOFIA Project Investigators Upper gastrointestinal symptoms and therapies in elderly out-patients, users of nonselective NSAIDs or coxibs. Aliment. Pharmacol. Ther., 2005, 22(2), 147-155. (Pubitemid 41039703)
64. Güzey, C.; Spigset, O. Genotyping as a tool to predict adverse drug reactions. Curr. Top. Med. Chem., 2004, 4(13), 1411-1421. (Pubitemid 39242882)
65. Higashi, M.K.; Veenstra, D.L.; Kondo, L.M.; Wittkowsky, A.K.; Srinouanprachanh, S.L.; Farin, F.M.; Rettie, A.E. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA, 2002, 287(13), 1690-1698. (Pubitemid 34289221)
66. Soga, Y.; Nishimura, F.; Ohtsuka, Y.; Araki, H.; Iwamoto, Y.; Naruishi, H.; Shiomi, N.; Kobayashi, Y.; Takashiba, S.; Shimizu, K.; Gomita, Y.; Oka, E. CYP2C9 polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci., 2004, 74(7), 827-834. (Pubitemid 37501131)
67. Kircheiner, J.; Brockmoller, J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther., 2005, 77(1), 1-15.
68. Klotz, U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int. J. Clin. Pharmacol. Ther., 2006, 44(7), 297-302. (Pubitemid 44043771)
69. Lou, H.Y.; Chang, C.C.; Sheu, M.T.; Chen, Y.C.; Ho, H.O. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur. J. Clin. Pharmacol., 2009, 65(1), 55-64.
70. Chasman, D.I.; Posada, D.; Subrahmanyan, L.; Cook, N.R.; Stanton, V.P. Jr.; Ridker, P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. J.A.M.A., 2004, 291(23), 2821-2827. (Pubitemid 38747801)
71. Medina, M.W.; Gao, F.; Ruan, W.; Rotter, J.I.; Krauss, R.M. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation, 2008, 118(4), 355-362.
72. Hirsh, J.; Fuster, V.; Ansell, J.; Halperin, J.L.; American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation, 2003, 107(12), 1692-1711. (Pubitemid 36397341)
73. FDA Approves Updated Warfarin (Coumadin) Prescribing Information New Genetic Information May Help Providers Improve Initial Dosing Estimates of the Anticoagulant for Individual Patients. Available at URL http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm.
74. Breckenridge, A.; Orme, M.; Wesseling, H. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther., 1974, 15(4), 424-430.
75. Lee, C.R.; Goldstein, J.A.; Pieper, J.A. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics, 2002, 12(3), 251-263. (Pubitemid 34596790)
76. Zhao, F.; Loke, C.; Rankin, S.C.; Guo, J.Y.; Lee, H.S.; Wu, T.S.; Tan, T.; Liu, T.C.; Lu, W.L.; Lim, Y.T.; Zhang, Q.; Goh, B.C.; Lee, S.C. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther., 2004, 76(3), 210-219. (Pubitemid 39221795)
77. Rane, A.; Lindh, J.D. Pharmacogenetics of anticoagulants. Hum. Genomics Proteomics, 2010, 2010, 754919.
78. Rieder, M.J.; Reiner, A.P.; Gage, B.F.; Nickerson, D.A.; Eby, C.S.; McLeod, H.L.; Blough, D.K.; Thummel, K.E.; Veenstra, D.L.; Rettie, A.E. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med., 2005, 352(22), 2285-2293. (Pubitemid 40740552)
79. Sandanaraj, E.; Lal, S.; Cheung, Y.B.; Xiang, X.; Kong, M.C.; Lee, L.H.; Ooi, L.L.; Chowbay, B. VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. Drug Metab. Pharmacokinet., 2009, 24(4),365-375.
80. Takeuchi, F.; McGinnis, R.; Bourgeois, S.; Barnes, C.; Eriksson, N.; Soranzo, N.; Whittaker, P.; Ranganath, V.; Kumanduri, V.; McLaren, W.; Holm, L.; Lindh, J.; Rane, A.; Wadelius, M.; Deloukas, P. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet., 2009, 5(3), e1000433.
81. Wadelius, M.; Chen, L.Y.; Lindh, J.D.; Eriksson, N.; Ghori, M.J.; Bumpstead, S.; Holm, L.; McGinnis, R.; Rane, A.; Deloukas, P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood, 2009, 113(4), 784-792.
82. International Warfarin Pharmacogenetics Consortium; Klein, T.E.; Altman, R.B.; Eriksson, N.; Gage, B.F.; Kimmel, S.E.; Lee, M.T.; Limdi, N.A.; Page, D.; Roden, D.M.; Wagner, M.J.; Caldwell, M.D.; Johnson, J.A. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 2009, 360(8), 753-764.
83. Manolopoulos, V.G.; Ragia, G.; Tavridou, A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11(4), 493-496.
84. Saminathan R, Bai J, Sadrolodabaee L, Karthik GM, Singh O, Subramaniyan K, Ching CB, Chen WN, Chowbay B. VKORC1 Pharmacogenetics and Pharmacoproteomics in Patients on Warfarin Anticoagulant Therapy: Transthyretin Precursor as a Potential Biomarker. PLoS One, 2010, 5(12), e15064.
85. Lewis, H.D., Jr.; Davis, J.W.; Archibald, D.G.; Steinke, W.E.; Smitherman, T.C.; Doherty, J.E., 3rd; Schnaper, H.W.; LeWinter, M.M.; Linares, E.; Pouget, J.M.; Sabharwal, S.C.; Chesler, E; De- Mots, H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med., 1983, 309(7), 396-403. (Pubitemid 13033964)
86. Shi, J.; Misso, N. L.; Kedda, M. A.; Horn, J.; Welch, M. D.; Duffy, D. L.; Williams, C.; Thompson, P. J. Cyclooxygenase-2 gene polymorphisms in an Australian population: association of the - 1195G > A promoter polymorphism with mild asthma. Clin. Exp. Allergy, 2008, 38(6), 913-920. (Pubitemid 351725859)
87. Shi, J.; Misso, N. L.; Duffy, D. L.; Bradley, B.; Beard, R.; Thompson, P. J.; Kedda, M. A. Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy. Eur. Respir. J., 2005, 26(2), 249-256. (Pubitemid 41079068)
88. Agúndez, J.A.; Martínez, C.; Pérez-Sala, D.; Carballo, M.; Torres, M.J.; García-Martín, E. Pharmacogenomics in aspirin intolerance. Curr. Drug Metab., 2009, 10(9), 998-1008.
89. van Oijen, M. G.; Koetsier, M. I.; Laheij, R. J.; Roelofs, H. M.; te Morsche, R. H.; Peters, W. H.; Verheugt, F. W.; Jansen, J. B.; Drenth, J. P. Genetic polymorphisms in UDP glucuronosyltransferase 1A6 are not associated with NSAIDs-related peptic ulcer haemorrhage. Drug Metab. Lett., 2009, 3(3), 199-204.
90. Shiotani, A.; Sakakibara, T.; Yamanaka, Y.; Nishi, R.; Imamura, H.; Fujita, M.; Tarumi, K.; Kamada, T.; Hata, J.; Haruma, K. The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. J. Gastroenterol., 2009, 44(7), 717-725.
91. Martinez, C.; Blanco, G.; Ladero, J. M.; Garcia-Martin, E.; Taxonera, C.; Gamito, F. G.; Diaz-Rubio, M.; Agundez, J. A. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol., 2004, 141(2), 205-208 (Pubitemid 38250889)
92. Vonkeman, H. E.; van de Laar, M. A.; van der Palen, J.; Brouwers, J. R.; Vermes, I. Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin. Ther., 2006, 28(10), 1670-1676. (Pubitemid 44841985)
93. Blanco, G.; Martinez, C.; Ladero, J. M.; Garcia-Martin, E.; Taxonera, C.; Gamito, F. G.; Diaz-Rubio, M.; Agundez, J. A. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastro-intestinal bleeding. Pharmacogenet. Genomics, 2008, 18(1), 37-43. (Pubitemid 351222384)
94. Agundez, J. A.; Martinez, C.; Garcia-Martin, E.; Ladero, J. M. Cytochrome P450 CYP2C9 polymorphism and NSAID-related acute gastrointestinal bleeding. Gastroenterology, 2007, 133(6), 2071-2072. (Pubitemid 350180821)
95. Knights, K. M.; Drogemuller, C. J. Xenobiotic-CoA ligases: kinetic and molecular characterization. Curr. Drug Metab., 2000, 1(1), 49-66.
96. Ha-Duong, N.T.; Dijols, S.; Macherey, A.C.; Goldstein, J.A.; Dansette, P.M.; Mansuy, D. Ticlopidine as a selective mechanismbased inhibitor of human cytochrome P450 2C19. Biochemistry, 2001, 40(40), 12112-12122. (Pubitemid 32946552)
97. Shuldiner, A.R.; O'Connell, J.R.; Bliden, K.P.; Gandhi, A.; Ryan, K.; Horenstein, R.B.; Damcott, C.M.; Pakyz, R.; Tantry, U.S.; Gibson, Q.; Pollin, T.I.; Post, W.; Parsa, A.; Mitchell, B.D.; Faraday, N.; Herzog, W.; Gurbel, P.A. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J.A.M.A., 2009, 302(8), 849-857.
98. Simon, T.; Verstuyft, C.; Mary-Krause, M.; Quteineh, L.; Drouet, E.; Méneveau, N.; Steg, P.G.; Ferriéres, J.; Danchin, N.; Becquemont, L; French Registry of Acute ST-Elevation and Non-STElevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med., 2009, 360(4), 363-375.
99. Collet, J.P.; Hulot, J.S.; Pena, A.; Villard, E.; Esteve, J.B.; Silvain, J.; Payot, L.; Brugier, D.; Cayla, G.; Beygui, F.; Bensimon, G.; Funck-Brentano, C.; Montalescot, G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet, 2009, 373(9660), 309-317.
100. Mega, J.L.; Close, S.L.; Wiviott, S.D.; Shen, L.; Hockett, R.D.; Brandt, J.T.; Walker, J.R.; Antman, E.M.; Macias, W.; Braunwald, E.; Sabatine, M.S. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med., 2009, 360(4), 354-362.
101. Mega, J.L.; Simon, T.; Collet, J.P.; Anderson, J.L.; Antman, E.M.; Bliden, K.; Cannon, C.P.; Danchin, N.; Giusti, B.; Gurbel, P.; Horne, B.D.; Hulot, J.S.; Kastrati, A.; Montalescot, G.; Neumann, F.J.; Shen, L.; Sibbing, D.; Steg, P.G.; Trenk, D.; Wiviott, S.D.; Sabatine, M.S. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. J.A.M.A., 2010, 304(16), 1821-1830.
102. Fuster, V.; Sweeny, J.M. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. J.A.M.A., 2010, 304(16), 1839-1840.
103. US Food and Drug Administration. Plavix (clopidogrel bisulfate) 75 mg tablets. May, 2009. http://www.fda.gov/Safety/Med- Watch/SafetyInformation/ ucm165166.htm (accessed Jan 6, 2011).
104. Bai, J.P. Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics. Drug Metab. Pharmacokinet., 2010, 25(1): 62-71.
105. Wallentin, L.; James, S.; Storey, R.F.; Armstrong, M.; Barratt, B.J.; Horrow, J.; Husted, S.; Katus, H.; Steg, P.G.; Shah, S.H.; Becker, R.C.; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet, 2010, 376(9749), 1320-1328.
106. Mega, J.L.; Close, S.L.; Wiviott, S.D.; Shen, L.; Walker, J.R.; Simon, T.; Antman, E.M.; Braunwald, E.; Sabatine, M.S. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet, 2010, 376(9749), 1312-1319.
107. Giusti, B.; Abbate, R. Response to antiplatelet treatment: from genes to outcome. Lancet, 2010, 376(9749), 1278-1281.
108. Rollason, V.; Samer, C.; Piguet, V.; Dayer, P.; Desmeules, J. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics, 2008, 9(7), 905-933.
109. König, J.; Seithel, A.; Gradhand, U.; Fromm, M.F. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol., 2006, 372(6), 432-443.
110. Seithel, A.; Glaeser, H.; Fromm, M.F.; König, J. The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert. Opin. Drug. Metab. Toxicol., 2008, 4(1), 51-64. (Pubitemid 351234100)
111. Brandsch, M.; Knütter, I.; Bosse-Doenecke, E. Pharmaceutical and pharmacological importance of peptide transporters. J. Pharm. Pharmacol., 2008, 60(5), 543-485.
112. Wadman, S.K.; Beemer, F.A.; de Bree, P.K.; Duran, M.; van Gennip, A.H.; Ketting D, van Sprang, F.G. New defects of pyrimidine metabolism. Adv. Exp. Med. Biol., 1984, 165 Pt A, 109-114.
113. Wei, X.; Elizondo, G.; Sapone, A.; McLeod, H.L.; Raunio, H., Fernandez- Salguero, P.; Gonzalez, F.J. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics, 1998, 51(3), 391-400. (Pubitemid 28413205)
114. van Kuilenburg, A.B; De Abreu, R.A.; van Gennip, A.H. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann. Clin. Biochem., 2003, 40(Pt 1), 41-45. (Pubitemid 36051408)
115. van Kuilenburg, A.B. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. Cancer Invest., 2006, 24(2), 215-217.
116. Yen, J.L.; McLeod, H.L. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur. J. 6.
117. Takeishi, K.; Kaneda, S.; Ayusawa, D.; Shimizu, K.; Gotoh, O.; Seno, T. Human thymidylate synthase gene: isolation of phage clones which cover a functionally active gene and structural analysis of the region upstream from the translation initiation codon. J. Biochem., 1989, 106(4), 575-583. (Pubitemid 19241824)
118. Horie, N.; Aiba, H.; Oguro, K.; Hojo, H.; Takeishi, K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell. Struct. Funct., 1995, 20(3), 191-197.
119. Kawakami, K.; Salonga, D.; Park, J.M.; Danenberg, K.D.; Uetake, H.; Brabender, J.; Omura, K.; Watanabe, G.; Danenberg, P.V. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res., 2001, 7(12), 4096-4101. (Pubitemid 34044633)
120. Uchida, K.; Hayashi, K.; Kawakami, K.; Schneider, S.; Yochim, J.M.; Kuramochi, H.; Takasaki, K.; Danenberg, K.D.; Danenberg, P.V. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin. Cancer Res., 2004, 10(2), 433-439. (Pubitemid 38173979)
121. Hitre, E.; Budai, B.; Adleff, V.; Czeglédi, F.; Horváth, Z.; Gyergyay, F.; Lövey, J.; Kovács, T.; Orosz, Z.; Láng, I.; Kásler, M.; Kralovánszky, J. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet. Genomics, 2005, 15(10), 723-730. (Pubitemid 41345324)
122. Sohn, K.J.; Croxford, R.; Yates, Z.; Lucock, M.; Kim, Y.I. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5- fluorouracil and methotrexate. J. Natl. Cancer Inst., 2004, 96(2), 134-144. (Pubitemid 38195904)
123. Coulthard, S.; Hogarth, L. The thiopurines: an update. Invest. New Drugs, 2005, 23(6), 523-532. (Pubitemid 43162471)
124. Vogt, M.H.; Stet, E.H.; De Abreu, R.A.; Bokkerink, J.P.; Lambooy, L.H.; Trijbels, F.J. The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts. Biochim. Biophys. Acta, 1993, 1181(2), 189-194. (Pubitemid 23124659)
125. Krynetski, E.Y.; Schuetz, J.D.; Galpin, A.J.; Pui, C.H.; Relling, M.V.; Evans, W.E. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl. Acad. Sci. USA, 1995, 92(4), 949-953.
126. Weinshilboum, R.M.; Sladek, S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet., 1980, 32(5), 651-662. (Pubitemid 10061685)
127. Schaeffeler, E.; Fischer, C.; Brockmeier, D.; Wernet, D.; Moerike, K.; Eichelbaum M.; Zanger, U.M.; Schwab, M. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics, 2004, 14(7), 407-417. (Pubitemid 38971231)
128. Tai, H.L.; Krynetski, E.Y.; Schuetz, E.G.; Yanishevski, Y.; Evans, W.E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. USA, 1997, 94(12), 6444-6449. (Pubitemid 27270704)
129. Schaeffeler, E.; Eichelbaum, M.; Reinisch, W.; Zanger, U.M.; Schwab, M. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum. Mutat., 2006, 27(9), 976.
130. Yates, C.R.; Krynetski, E.Y.; Loennechen, T.; Fessing, M.Y.; Tai, H.L.; Pui, C.H.; Relling, M.V.; Ewans, W.E. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med., 1997, 126(8), 608-614. (Pubitemid 27172187)
131. Stanulla, M.; Schaeffeler, E.; Flohr, T.; Cario, G.; Schrauder, A.; Zimmermann, M.; Welte, K.; Ludwig, W.D.; Bartram, C.R.; Zanger, U.M.; Eichelbaum, M.; Schrappe, M.; Schwab, M. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA, 2005, 293(12), 1485-1489. (Pubitemid 40393293)
132. Kadakol, A.; Ghosh, S.S.; Sappal, B.S.; Sharma, G.; Chowdhury, J.R.; Chowdhury, N.R. Genetic lesions of bilirubin uridinediphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum. Mutat., 2000, 16(4), 297-306.
133. Sugatani, J.; Yamakawa, K.; Yoshinari, K.; Machida, T.; Takagi, H.; Mori. M.; Kakizaki, S.; Sueyoshi, T.; Negishi, M.; Miwa, M. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun., 2002, 292(2), 492-497. (Pubitemid 34694291)
134. langer, P.; Journault, K.; Gaucher, G.; Guillemette, C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN- 38). Mol. Pharmacol., 2002, 62(3) 608-617. (Pubitemid 36329379)
135. Bosma, P.J.; Chowdhury, J.R.; Bakker, C.; Gantla, S.; de Boer, A.; Oostra, B.A.; Lindhout, D.; Tytgat, G.N.J.; Jansen, P.L.M.; Oude Elferink R.P.J.; Chowdhury, N.R. The genetic basis of the reduced expression of bilirubin UDP glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med., 1995, 333(18), 1171-1175.
136. Sweeney, C.; McClure, G.Y.; Fares, M.Y.; Stone, A.; Coles, B.F.; Thompson, P.A.; Korourian, S.; Hutchins, L.F.; Kadlubar, F.F.; Ambrosone, C.B. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res., 2000, 60(20), 5621-5624.
137. Stoehlmacher, J.; Park, D.J.; Zhang, W.; Groshen, S.; Tsao-Wei, D.D.; Yu, M.C.; Lenz, H.J. Association between glutathione Stransferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst., 2002, 94(12), 936-942. (Pubitemid 34778092)
138. Tang, K.; Ngoi, S.M.; Gwee, P.C.; Chua, J.M.; Lee, E.J.; Chong, S.S.; Lee, C.G. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002, 12(6), 437-450. (Pubitemid 34913526)
139. Wong, M.; Evans, S.; Rivory, L.P.; Hoskins, J.M.; Mann, G.J.; Farlow, D.; Clarke, C.L.; Balleine, R.L.; Gurney, H. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (Pglycoprotein) activity in patients with cancer. Clin. Pharmacol. Ther., 2005, 77(1), 33-42. (Pubitemid 40075387)
140. Sai, K.; Itoda, M.; Saito, Y.; Kurose, K.; Katori, N.; Kaniwa, N.; Komamura, K.; Kotake, T.; Morishita, H.; Tomoike, H.; Kamakura, S.; Kitakaze, M.; Tamura, T.; Yamamoto, N.; Kunitoh, H.; Yamada, Y.; Ohe, Y.; Shimada, Y.; Shirao, K.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Kamatani, N.; Ozawa, S.; Sawada, J. Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, and associated ethnic differences. Ann. Hum. Genet. 2006, 70(Pt 5), 605-622. (Pubitemid 44173372)
141. Zhou, Q.; Sparreboom, A.; Tan, E.H.; Cheung, Y.B.; Lee, A.; Poon, D.; Lee, E.J.; Chowbay, B. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br. J. Clin. Pharmacol., 2005, 59(4), 415-424. (Pubitemid 40523885)
142. Mathijssen, R.H.; Marsh, S.; Karlsson, M.O.; Xie, R.; Baker, S.D.; Verweij, J.; Sparreboom, A.; McLeod, H.L. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res., 2003, 9(9), 3246-3253. (Pubitemid 37086673)
143. de Jong, F.A.; Marsh, S.; Mathijssen, R.H.; King, C.; Verweij, J.; Sparreboom, A.; McLeod, H.L. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res., 2004, 10(17), 5889-5894. (Pubitemid 39180970)
144. de Jong, F.A.; Scott-Horton, T.J.; Kroetz, D.L.; McLeod, H.L.; Friberg, L.E.; Mathijssen, R.H.; Verweij, J.; Marsh, S.; Sparreboom, A. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther., 2007, 81(1), 42-49. (Pubitemid 46050866)
145. Ingelman-Sundberg, M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N. Engl. J. Med., 2008, 358(6), 637-639. (Pubitemid 351214293)
146. Al-Ghoul, M.; Valdes, R.Jr.; Fundamentals of pharmacology and applications in pharmacogenetics. Clin. Lab. Med., 2008, 28(4), 485-497.